Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Starpharma Holdings Limited ( (AU:SPL) ).
Starpharma Holdings Limited has entered into a collaboration and license agreement with Genentech, a Roche Group member, to develop cancer therapies using Starpharma’s DEP® technology. This partnership will see Starpharma receive an upfront payment and potential milestone payments totaling up to USD $564 million, along with royalties on global sales. The collaboration highlights Starpharma’s strategic focus on forming impactful partnerships to expand its market reach and enhance therapeutic offerings, positioning the company strongly within the oncology sector.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which it has been advancing for over two decades. The company focuses on developing drug delivery technologies, particularly through its proprietary DEP® platform, which enhances drug solubility, efficacy, and toxicity profiles. Starpharma’s technology is applicable across various drug classes, including small molecules, peptides, proteins, chemotherapeutics, and antibody-drug conjugates.
YTD Price Performance: 18.18%
Average Trading Volume: 318,370
Technical Sentiment Signal: Hold
Current Market Cap: A$54.37M
Find detailed analytics on SPL stock on TipRanks’ Stock Analysis page.